Gridelli showed that single-agent vinorelbine or single-agent gemcitabine provided the same survival with less toxicity than the combined regimen3.

• Gridelli报道的MILES研究显示，诺维本单药或健择单药与联合用药相比，生存期相似、毒性较低。